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The Patchliner®temperature-controlled automated patch clamp system was evaluated for
testing drug effects on potassium currents through human ether-à-go-go related gene
(hERG) channels expressed in Chinese hamster ovary cells at 35–37˚C. IC50 values for a
set of reference drugs were compared with those obtained using the conventional voltage
clamp technique. The results showed good correlation between the data obtained using
automated and conventional electrophysiology. Based on these results, the Patchliner®
represents an innovative automated electrophysiology platform for conducting the hERG
assay that substantially increases throughput and has the advantage of operating at phys-
iological temperature. It allows fast, accurate, and direct assessment of channel function
to identify potential proarrhythmic side effects and sets a new standard in ion channel
research for drug safety testing.
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INTRODUCTION
The cardiac proarrhythmic liability of new pharmacological enti-
ties is a major concern for pharmaceutical companies and regu-
latory agencies. Remarkably, many if not most compounds exert
their arrhythmogenic effects through the same electrophysiologi-
cal mechanism: blockade of repolarizing currents through human
ether-à-go-go related gene (hERG) K+ channels located in ven-
tricular myocytes (Sanguinetti and Tristani-Firouzi, 2006). As a
result, in-vitro hERG assay has been introduced into the drug
development process to test the proarrhythmic potential of small
molecules (International Conference on Harmonisation, 2005).
The assay evaluates the acute effects of new therapeutic agents on
hERG channels stably expressed in mammalian cell lines (such
as HEK293 and CHO cells). By directly measuring a compound’s
ability to block hERG K+ channels it evaluates the proarrhyth-
mic liability associated with this fairly common arrhythmogenic
mechanism.
The gold standard for assessing ion channel functionality is the
patch clamp technique. The high-resolution conventional man-
ual method involves a glass micropipette ﬁlled with an ionic
solution that electrically connects an electrode wire to a small
patch of cell membrane. Considerable expertise is needed and
throughput is low as only one cell can be recorded at a time.
In addition, accurate drug safety assessment requires a highly
sensitive temperature-controlled patch clamp since the current
kinetics is temperature-dependent and inappropriate experimen-
tal temperature may compromise the pharmacological proper-
ties of the hERG current (Vandenberg et al., 2006). Thus thor-
ough analysis of hERG liabilities under physiological condi-
tions has only been possible to date for advanced compounds
using the conventional manual patch clamp technique. How-
ever, the high attrition rate due to cardiovascular adverse effects
indicated a strong need for a high-quality electrophysiological
method for early hERG proﬁling of a larger number of drug
candidates.
Fortunately, automation has entered the area of experimen-
tal electrophysiology over the past few years. The ﬁrst automated
patch clamp instruments focused on increasing throughput by the
parallel formation of high-resistance seals using the planar patch
clamp at ambient temperature (reviewed in Möller, 2010). Var-
ious companies have recently launched second-generation auto-
mated platforms, including the Patchliner® (Nanion Technologies
GmbH, Munich, Germany), a fully automated patch clamp sys-
tem with integrated temperature control. The planar NPC® chip
electrode combined with temperature control add-on is designed
to control giga-Ohm seal formation at 35–37˚C and accurately
maintain temperatures over an experiment. By recording from
up to eight cells simultaneously at physiological temperature, the
Patchliner® claims to substantially increase through put without
compromising data quality.
The objective of the present study was to transfer the hERG
assay at physiological temperature to the Patchliner® and eval-
uate the automated platform for its ability to correctly deter-
mine potency and IC50 values for reference compounds including
known hERG blockers and negative controls.
MATERIALS AND METHODS
CELL CULTURE
The CHO crelox hERG cell line (ATCC reference Nr. PTA-6812)
was generated and validated at Roche (Guthrie et al., 2005).
Recombinant hERG K+ channels originally cloned from human
heart were stably expressed in CHO cells grown in sterile tissue
ﬂasks in DMEM/F-12 (1:1) medium (Invitrogen, USA) supple-
mented with 10% (v/v) heat-inactivated fetal calf serum (FCS)
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(Hyclone, USA) and 500μg/ml gentamycin solution (Gibco, UK)
at 35–37˚C in 5% CO2.
Conﬂuent cell cultures were subcultured every 2–3 days using
Accumax (Innovative Cell Technologies Inc., USA). Before elec-
trophysiological experiments, cells were treated with Accumax for
3–5 min at 42˚C, harvested, and centrifuged at 1000 rpm for 1 min.
The pellet was gently resuspended in the extracellular solution and
directly used for electrophysiological recording.
SOLUTIONS
The extracellular solution contained (mM): NaCl 150; KCl 4;
CaCl2 1.2; MgCl2 1; HEPES 10; pH 7.2–7.6 with NaOH, osmolar-
ity 290–330 mOsm. The internal solution contained (mM): KCl,
50; KF, 60; NaCl, 10; HEPES, 10; EGTA, 20; pH 7.0–7.4 with KOH,
osmolarity 260–300 mOsm.
All solutionswereﬁltered through0.2μMGPMilliporeExpress
PLUS membrane and stored in aliquots at +2–8˚C.
COMPOUNDS
Olanzapine was synthesized by Roche (Basel, Switzerland). Amio-
darone, astemizole, bepridil, clemastine, haloperidol, terfena-
dine, and verapamil were purchased from Sigma (USA), cis-
apride from Research Diagnostic Inc. (USA), E-4031 from
Wako Chemicals (Japan), quinidine from Aldrich Chemicals
(USA), d,l-Sotalol from Bristol-Myers-Squibb (USA), amoxi-
cillin, ﬂuoxetine, isradipine, and tamoxifen from USP (USA),
glyburide/glibenclamide fromCalbiochem(USA), ibuprofen from
ICN Biomedicals Inc. (USA), moxiﬂoxacin from APIChem Tech-
nologies Co. (China), and erythromycin and captopril from Fluka
(Switzerland).
Selection of test concentrations for each compound was done
based on the hERG potency data and the solubility in the extracel-
lular solution. Stock solutions of compoundswere freshly prepared
in DMSO. Test solutions were made such that solvent concen-
trations were kept constant throughout the experiment (0.1%).
Compound solutions were transferred to 4 mL glass vials that were
placed in the compound plate holder of the patch clamp system
(Figure 1).
AUTOMATED PATCH CLAMP PROCEDURES ON THE PATCHLINER®
On the day of the experiment, an aliquot of the cell suspension in
the extracellular solution was placed in the cell hotel (Figure 1).
Cells were added to each chip well and attracted to the holes by
suction applied by a pressure controller. Once a stable whole-cell
conﬁguration was obtained, the experimental protocol was ini-
tiated. K+ currents were measured with a patch–voltage-clamp
technique in the whole-cell conﬁguration at 35–37˚C using the
QuadroEPC-10 ampliﬁer (HEKA Elektronik GmbH, Germany)
and associated software (Patch MasterPro). Currents were low-
pass ﬁltered using the internal Bessel ﬁlter of the EPC-10 and
digitized at 50 kHz. Series resistance was typically 2–4 MΩ and
compensated 70–80%.
Cells were held at a resting voltage of −80 mV and stimulated
by a voltage pattern to activate hERG channels and conduct out-
ward IKhERG current (Figure 2, bottom panel), at a stimulation
frequency of 0.1 Hz (6 bpm). The reported current amplitudes
represent the maximal peak tail current. After the cells stabilized
FIGURE 1 |The Patchliner® is shown at the top panel and a closer view
of the working area is presented below.
for a few minutes and currents were steady, IKhERG amplitude and
kinetics were recorded under control conditions (vehicle control)
for 3–5 min. Thereafter, a single test item concentration was added
and incubated for at least 3 min until a new steady state current
level was reached (see Figures 3 and 4 for the experimental pro-
cedure). At the end of the compound incubation, a 1μM solution
of standard IKhERG blocker E-4031 was applied twice to each cell
for 1 min to suppress IKhERG entirely.
IKhERG amplitudes were recorded at four to ﬁve drug concen-
trations. The hERG current was measured as the average current
from ﬁve sweeps collected at the end of vehicle or compound addi-
tion. After subtracting current levels from that of full block (i.e.,
positive control) they were compared to the vehicle control values
(taken as 100%) to deﬁne fractional blocks. The fractional block
values at single concentrations were saved in the appropriate.xls
ﬁle generated by PatchControlHT software (Nanion). Data were
expressed as mean± SEM for each drug concentration and were
used to determine the concentration–response relationship for the
test compounds. The effect of the solvent (DMSO) on the hERG
K+ current was studied in a vehicle control group.
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FIGURE 2 |The top panel shows typical outward K+ current traces elicited in CHO-hERG cells by the voltage pulse depicted at the bottom panel (the
area for the peak current measurement is highlighted in red).
FIGURE 3 |Time course of hERG K+ current amplitude recorded in a
representative vehicle control experiment on the Patchliner®. Cells were
exposed sequentially to vehicle (0.1% v/v DMSO), compound (0.1% v/v
DMSO), and 1μM E-4031. Arrows indicate compound additions.
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FIGURE 4 | Examples of pharmacological experiments on the
Patchliner®. Recordings from four cells were performed in parallel.
Original traces are shown in the middle with the on-line analysis
window showing the time course of a compound effect on the peak
hERG K+ current to the right. Arrows indicate compound additions for
vehicle (0.1% v/v DMSO), test item single concentration [0.3μM
quinidine in (A) and 6μM glibenclamide in (B)] and positive control
(1μM E-4031).
DATA ANALYSIS
If the effect of a drug on the currents was ≤20% at the highest
concentration tested, IC50 was reported as exceeding the highest
concentration value. If the effect of a drug on the currents exceeded
20% at the highest concentration tested, then concentration–
response data from three to ﬁve cells were normalized to vehicle
and 100% blocking levels and the resulting data ﬁtted with the
following relationship:
I (C) = 100
1 + (C/IC50
)h
where C was the concentration, IC50 the 50% inhibitory concen-
tration, h the Hill coefﬁcient.
Concentration–response curves were ﬁtted by non-linear
regression analysis using the XL ﬁt add-in (IDBS Ltd.,
UK). Data were ﬁtted using a four-parameter logistic model
[ﬁt= (A + (B/(1+ ((x/C)∧D)))], where A = 0 and B = 100).
Statistical analysis was performed using two-way ANOVA
with the Bonferroni post-test, applying the correction for mul-
tiple comparison at a signiﬁcance level of p< 0.05 with Graph-
Pad Prism 5 for Windows (GraphPad Software, USA). Cor-
relation between assays [Pearson’s coefﬁcient (r)] and values
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for statistical signiﬁcance (p) were determined using GraphPad
Prism.
RESULTS
The Patchliner® work station shown in Figure 1 uses NPC-16
borosilicate glass chips with a microﬂuidic cartridge for parallel
seal formation and patch clamp recordings from up to eight dif-
ferent wells. In this study, a simultaneous recording from four cells
exposed to the same compound concentration was performed,
resulting in a four-point dose–response curve with one chip car-
tridge, containing 16 recording wells in total. After priming, cells
were captured on the holes of the chip by applying continuous
vacuum pressure. After allowing current to stabilize in the whole-
cell conﬁguration, a quality control check was performed before
starting treatment to ensure that only recordings with true giga-
Ohm-seals and a minimum current of 300 pA were included in
the experiment. The seal resistance varied between 3.9 ± 2.6 GΩ
at the start and 3.2± 2.1 GΩ at the end of the experiment while the
average current amplitude was 0.9± 0.6 nA (mean± SD, n = 297
cells). Typical examples of the hERG current traces are shown
in Figure 2. The recordings remained stable for over 30 min
at physiological temperature enabling subsequent conduction of
compound incubation followed by exposure to the positive con-
trol at each concentration with an overall success rate >70%. Cells
were maintained in suspension for over 2 h in a cell hotel with
no associated decline in patch properties. The sealing quality was
very high with the giga-Ohm-seal formation and the whole-cell
transition rates almost reaching 100%on the Patchliner®. On aver-
age, three out of four cells maintained giga-Ohm-seals and stable
currents until the end of the experiments.
Vehicle effect (0.1% v/v DMSO) on the hERG current was
studied in time-matched vehicle control groups (Figure 3). These
controlmeasurementswere performed once aweek during the val-
idation period. The largest reduction in the outward K+ current
magnitude (mean± SEM) produced by the subsequent applica-
tion of a vehicle alone to the CHO cells expressing recombinant
hERGK+ channels was 6± 1% (Table 1). This indicates that expo-
sure to solvent may produce only a slight signiﬁcant effect on the
current with time. Therefore, the relative current values were cor-
rected appropriately to the mean vehicle effect at each test item
concentration as follows:
Icorrected (%) = Itest
meanIvehicle
× 100
where I was the relative current amplitude.
To validate the utility of the Patchliner® for the hERG assay, the
actions of reference drugs on the hERG current were examined
at physiological temperature. A set of 21 compounds includ-
ing known hERG blockers and negative controls was evaluated.
Examples of pharmacological experiments on the Patchliner® are
shown in Figure 4. Obtained IC50 values (Table 2) were plot-
ted against those obtained using the conventional voltage clamp
technique. Manual patch clamp data for reference drugs were
either generated in-house using theCHO–hERGcells and identical
experimental conditions (solutions and voltage step protocol) or
taken from published literature. Literature hERGIC50 values were
carefully selected to match such key experimental parameters as
temperature, expression system, and voltage protocol.
Table 1 | Effects of 0.1% (v/v) DMSO on the hERG K+ current.
hERG current (% of control)
Mean SD N p
30min 98 7 17 >0.05
60min 97 6 19 >0.05
90min 94 5 19 <0.001
120min 94 6 14 <0.001
FIGURE 5 | Correlation of the hERG IC50 values obtained in the
automated temperature-controlled Patchliner® system (PL) with those
measured using the conventional manual patch clamp (PC) at 37˚C.
The hERG potencies of all reference drugs were correctly iden-
tiﬁed. Amiodarone, astemizole, cisapride, clemastine, E-4031, and
terfenadine were by far the strongest hERG inhibitors of the com-
pounds tested, with IC50 values in the low and mid-nanomolar
range. Some drugs, such as olanzapine, moxiﬂoxacin, sotalol,
tamoxifen, and verapamil, showed an intermediate effect on the
hERG current. Captopril, ibuprofen, and glibenclamide did not
affect the hERG current up to the highest concentration tested.
Comparison of the results showed statistically signiﬁcant cor-
relation (r = 0.9989, p< 0.0001) between the data obtained at
physiological temperature on the Patchliner® and those using the
conventional patch clamp rigat the same temperature (Figure 5).
DISCUSSION
The hERG test has become the routine in vitro approach for assess-
ing the cardiac safety of new drugs in early development. Since
some compounds exhibit temperature-dependent potency shifts
(Yao et al., 2005),performing experiments at physiological temper-
ature improves the relevance of pharmacological data and ensures
more accurate cardiac risk assessment in vivo. Until recently,
the manual patch clamp was the only technique for conduct-
ing temperature-controlled electrophysiological measurements.
However, its low throughput hampered functional early proﬁling
of large compound series for proper clinical candidate selection.
The availability of a predictive cost–effective hERG assay based on
efﬁcient high-resolution technology is thus of major importance
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Table 2 | Effects of reference drugs on the hERG K+ current.
Compound Test conc. PL (μM) hERGIC50 PL (μM) hERG IC50 PC (μM)
Mean±SE
Amiodarone 0.01–0.03–0.1–0.3 0.17±0.03 0.070 (Ridley et al., 2004)
Astemizole 0.001–0.003–0.01–0.03 0.012±0.0008 0.006
Bepridil 0.01–0.03–0.1–0.3 0.065±0.012 0.27
Captopril 1–10–100–1000 >1000 >1000
Cisapride 0.001–0.01–0.1–1 0.022±0.005 0.024 (Walker et al., 1999)
Clemastine 0.001–0.01–0.1–1 0.006±0.002 0.012 (Ridley et al., 2006)
Dofetilide 0.001–0.01–0.1–1 0.058±0.018 0.01 (Du et al., 2011)
E-4031 0.0003–0.003–0.03–0.3 0.001±0.0002 0.002
Erythromycin 1–10–100–1000 257±28 236
Fluoxetine 0.1–0.3–1–3 0.39±0.05 2.0
Glibenclamide 0.2–0.6–2–6 >6 >6
Haloperidol 0.001–0.01–0.1–1 0.023±0.005 0.027
Ibuprofen 0.3–3–30–300 >300 >300
Moxiﬂoxacin 0.3–3–30–300 34±2 29 (Alexandrou et al., 2006)
Olanzapine 0.3–1–3–10 1.3±0.2 2.1
Quinidine 0.1–0.3–1–3 0.35±0.06 0.6
d,l-Sotalol 0.3–3–30–300 103±20 154
Tamoxifen 0.1–0.3–1–3 0.44±0.06 0.1 (Yuill et al., 2004)
Terfenadine 0.003–0.01–0.03–0.3 0.05±0.01 0.015
Thioridazine 0.03–0.1–0.3–1–3 0.09±0.003 0.096 (Kirsch et al., 2004)
Verapamil 0.01–0.003–0.1–0.3 0.2±0.03 0.136 (Kirsch et al., 2004)
for the pharmaceutical industry. A recent publication by Golden
et al. (2011) described a ﬁrst attempt to evaluate the hERG chan-
nel physiology at 37˚C using an automated sub-giga-Ohm planar
patch clamp IonFlux system from Fluxion with a satisfactory out-
come. The present study aimed to evaluate theNanion Patchliner®,
a novel automated electrophysiological workstation, for hERG
testing under physiological conditions.
The Patchliner® has been successfully introduced as a high-
quality medium throughput automated planar patch clamp plat-
form for ion channel research in drug discovery and safety (review
in Farre et al., 2009). A unique feature is its ability to conduct
stable recordings at different temperatures in the 22–60˚C range.
The results of the present study showed that the Patchliner®
gives high-quality patch clamp recordings in CHO-hERG cells,
with a high success rate of giga-Ohm-seals lasting up to an
hour at 37˚C. Such performance makes the system a powerful
tool for studying hERG channel pharmacology at physiological
temperature.
In this work, a systematic comparison of diverse panel of refer-
ence drugs spanning a broad hERG potency range was performed
to validate the Patchliner® for temperature-controlled hERG assay.
The obtained IC50s values were compared with their manual patch
clamp counterparts. The main ﬁnding was that the potency data
generated on the Patchliner® matched those obtained by the con-
ventional method (Pearson r = 0.9989, p< 0.0001). It is impor-
tant to note that among the drugs tested, the inhibitory effects
of d,l-sotalol and erythromycin (Kirsch et al., 2004) were cor-
rectly identiﬁed at 37˚C. The Patchliner® system allowed fast and
accurate electrophysiological characterizationof ion channels, e.g.,
for determining the IC50 values of ion channel blockers.
In addition to the standard test, the Patchliner® could be a
useful tool for studying temperature-dependent potency shifts
and new mechanisms of compound action, e.g., the kinetics of
recovery after full inhibition of the hERG current that may pro-
vide valuable guidance for drug candidate identiﬁcation (Swinney,
2009). An additional advantage of the system is that experiments
can be preprogrammed and executed in a stand-alone mode.
Thus the results of the present study indicate that the Patchliner®
can be successfully used to produce high-quality data similar to
those obtained by means of the current gold standard, the manual
patch clamp. The system is unique in combining the features of
high-quality patch clamp recordings with increased physiological
relevance of the collected data, resulting in the enhanced safety
proﬁling of new chemical entities.
CONCLUSION
The Patchliner® workstation provides stable currents and high-
quality giga-Ohm-seal recordings at 37˚C. Based on the validation
results, this automated electrophysiology workstation can be used
for conducting an advanced hERG assay for new compounds at
physiological temperature and may eventually become a new gold
standard for ion channel research in safety pharmacology.
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